文献速递神经免疫认知障碍与痴呆

利用急性视神经炎试验评估多发性硬化的神经保护与髓鞘再生治疗

Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2020-01-01

AON-VisualPath前瞻性队列研究纳入60例急性视神经炎患者,随访18个月,用OCT、视力及mfVEP评估视网膜结构改变与视觉终点关联。结果显示GCIPL早期快速变薄,6个月双眼间2.5%低对比度字母视力差与视网膜神经纤维层及GCIPL变薄和mfVEP潜伏期变化相关;估算6个月双臂试验每组37或50例可检测50%疗效。

要点

  • 急性视神经炎是测试神经保护与髓鞘再生治疗的合适条件。
  • 6个月双眼间2.5%低对比度字母视力差与视网膜结构及mfVEP变化强相关。
  • 小样本短期试验即可评估神经保护和髓鞘再生疗效。

核心结论

  • 急性视神经炎可在急性炎症后测试神经保护和髓鞘再生治疗,提供敏感标志物评估两种过程及视觉恢复。

研究设计与样本

  • AON-VisualPath前瞻性队列研究,2011年2月至2018年11月在巴塞罗那大学医院开展,连续纳入60例急性视神经炎患者并随访18个月。

主要发现

  • 前4周GCIPL厚度以约2.38 μm/周速率变薄。
  • 急性视神经炎眼6个月mfVEP潜伏期变化约20毫秒,健康眼随机变异预期变化0.13(95%CI -0.80至1.06)毫秒。
  • 6个月双眼间2.5%低对比度字母视力差与pRNFL变薄(校正R2 0.57)、GCIPL变薄(校正R2 0.50)及mfVEP潜伏期变化(校正R2 0.26)相关。
  • 基线高对比度视力每增加5个字母,6个月pRNFL变薄减少1.41(95%CI 0.60-2.23)μm(P=.001;校正R2 0.20),GCIPL变薄减少0.86(95%CI 0.35-1.37)μm(P=.001;校正R2 0.19),但与mfVEP潜伏期变化无关。

关键数值与推荐

  • 检测GCIPL变薄50%疗效需6个月双臂平行组试验每组37例(把握度80%,α=.05)。
  • 检测mfVEP潜伏期变化50%疗效需每组50例(把握度80%,α=.05)。

临床怎么用

  • 可将急性视神经炎作为多发性硬化神经保护和髓鞘再生治疗的试验模型,利用OCT和mfVEP标志物在较短时间内以小样本评估疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Neuroprotective and remyelinating therapies are required for multiple sclerosis (MS), and acute optic neuritis (AON) is a potential condition to evaluate such treatments. OBJECTIVE: To comprehensively assess key biological and methodological aspects of AON trials for testing neuroprotection and remyelination in MS. DESIGN, SETTING, AND PARTICIPANTS: The AON-VisualPath prospective cohort study was conducted from February 2011 to November 2018 at the Hospital Clinic of University of Barcelona, Barcelona, Spain. Consecutive patients with AON were prospectively enrolled in the cohort and followed up for 18 months. Data analyses occurred from November 2018 to February 2019. EXPOSURES: Participants were followed up for 18 months using optical coherence tomography, visual acuity tests, and in a subset of 25 participants, multifocal visual evoked potentials. MAIN OUTCOMES AND MEASURES: Dynamic models of retinal changes and nerve conduction and their associations with visual end points; and eligibility criteria, stratification, and sample-size estimation for future trials. RESULTS: A total of 60 patients (50 women [83%]; median age, 34 years) with AON were included. The patients studied displayed early and intense inner retinal thinning, with a thinning rate of approximately 2.38 μm per week in the ganglion cell plus inner plexiform layer (GCIPL) during the first 4 weeks. Eyes with AON displayed a 6-month change in latency of about 20 milliseconds, while the expected change in the eyes of healthy participants by random variability was 0.13 (95% CI, -0.80 to 1.06) milliseconds. The strongest associations with visual end points were for the 6-month intereye difference in 2.5% low-contrast letter acuity, which was correlated with the peripapillary retinal nerve fiber layer thinning (adjusted R2, 0.57), GCIPL thinning (adjusted R2, 0.50), and changes in mfVEP latency (adjusted R2, 0.26). A 5-letter increment in high-contrast visual acuity at presentation (but not sex or age) was associated with 6-month retinal thinning (1.41 [95% CI, 0.60-2.23] μm less peripapillary retinal nerve fiber layer thinning thinning; P = .001; adjusted R2, 0.20; 0.86 [95% CI, 0.35-1.37] μm less GCIPL thinning; P = .001; adjusted R2, 0.19) but not any change in multifocal visual evoked potential latency. To demonstrate 50% efficacy in GCIPL thinning or change in multifocal visual evoked potential latency, a 6-month, 2-arm, parallel-group trial would need 37 or 50 participants per group to test a neuroprotective or remyelinating drug, respectively (power, 80%; α, .05). CONCLUSIONS AND RELEVANCE: Acute optic neuritis is a suitable condition to test neuroprotective and remyelinating therapies after acute inflammation, providing sensitive markers to assess the effects on both processes and prospective visual recovery within a manageable timeframe and with a relatively small sample size.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Andorrà M, Alba-Arbalat S, Camos-Carreras A, et al. Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. JAMA Neurol. 2020. PMID: 31566686. doi:10.1001/jamaneurol.2019.3283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。